Compare ELA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELA | RLMD |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.7M | 524.9M |
| IPO Year | 1995 | 2012 |
| Metric | ELA | RLMD |
|---|---|---|
| Price | $21.32 | $5.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $16.50 | $12.40 |
| AVG Volume (30 Days) | 123.8K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.38 | 45.28 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $241,021,362.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.54 | N/A |
| P/E Ratio | $60.74 | ★ N/A |
| Revenue Growth | 33.62 | ★ 154.83 |
| 52 Week Low | $5.42 | $0.55 |
| 52 Week High | $29.68 | $8.00 |
| Indicator | ELA | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 34.95 |
| Support Level | $16.31 | $4.06 |
| Resistance Level | $28.56 | $7.28 |
| Average True Range (ATR) | 1.09 | 0.39 |
| MACD | -0.21 | -0.08 |
| Stochastic Oscillator | 22.99 | 19.83 |
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.